Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos, Harleen Muhar, Shawn Smith
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1089-1101
Open Access | Times Cited: 12

Showing 12 citing articles:

Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 7
GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
Ahlima Roumane, George D. Mcilroy, Nadine Sommer, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Appendicitis After Initiation of Tirzepatide
Gilbert Chan, M. Ansar, Melissa Klein
Diabetes Metabolic Syndrome and Obesity (2025) Vol. Volume 18, pp. 261-265
Open Access
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 2
Development of Novel N-Acylhydrazone Derivatives with High Anti-obesity Activity and Improved Safety by Exploring the Pharmaceutical Properties of Aldehyde Group
Zhi Jiang, Yu‐Tao Hu, Shi‐Yao Guo, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 12439-12458
Closed Access | Times Cited: 1
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits
Xuan Xia, Qianmeng Lin, Zhan Zhou, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109377-109377
Open Access
In vivo Antibody Painting for Next Generation Weight Loss Drugs
Katsushi Kitahara, Aurélie Rondon, Edward Miller, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Is physical activity still the key to treating obesity? - semaglutide, a new position among therapies
Karolina Makowska, Marta Billewicz, Aleksandra Marczyk, et al.
Quality in Sport (2024) Vol. 20, pp. 54194-54194
Open Access
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Vincenzo Rochira, Carla Greco, Stefano Boni, et al.
Diseases (2024) Vol. 12, Iss. 9, pp. 204-204
Open Access
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1479-1479
Open Access
Biotechnology Revolution Shaping the Future of Diabetes Management
Nilima Rajpal Kundnani, Bogdan M. Lolescu, Anca Raluca Dinu, et al.
Biomolecules (2024) Vol. 14, Iss. 12, pp. 1563-1563
Open Access
Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
Kali Morrissette, Stefan Hansen, Michelle Pavlis, et al.
Cureus (2024)
Open Access
GLP-1 Receptor Agonist Improves Metabolic Disease in a Pre-clinical Model of Lipodystrophy
Ahlima Roumane, George D. Mcilroy, Nadine Sommer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top